|
WO2020169698A1
|
|
Sensitization of cancer cells to tnf by bet inhibition
|
|
WO2020169731A1
|
|
Valve for transferring at least one fluid
|
|
WO2020169666A1
|
|
Improved nucleic acid target enrichment and related methods
|
|
WO2020157083A1
|
|
Assessing progression of huntington's disease
|
|
CA3088355A1
|
|
Treatment of ophthalmologic diseases
|
|
CA3087930A1
|
|
A method for controlling distribution of a product in a computer network and system
|
|
WO2020156683A1
|
|
Aleglitazar for use in the treatment or prevention of major adverse cardiac events
|
|
AR114001A1
|
|
ANTIBODIES THAT JOIN HLA-A2 / WT1
|
|
KR20200079492A
|
|
Bispecific 2+1 connector
|
|
EP3704145A1
|
|
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
|
BR112019026389A2
|
|
method to diagnose paroxysmal atrial fibrillation, method to assist in the diagnosis of paroxysmal atrial fibrillation and its uses
|
|
EP3559269A1
|
|
Single stranded circular dna libraries for circular consensus sequencing
|
|
WO2018015240A1
|
|
New difluoroketamide derivatives as htra1 inhibitors
|
|
WO2018011160A1
|
|
6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
|
WO2018007331A1
|
|
Fused pyrimidine derivatives
|
|
WO2017220516A1
|
|
Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
|
|
WO2017211791A1
|
|
Combination therapy of an hbsag inhibitor and a tlr7 agonist
|
|
EP3252078A1
|
|
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2017207696A1
|
|
Novel mutations in anaplastic lymphoma kinase predicting response to alk inhibitor therapy in lung cancer patients
|
|
WO2017207600A1
|
|
New treatment of sma
|
